Tip-Loaded Microneedle Arrays for Precise Transdermal Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional microneedle arrays for transdermal drug delivery face challenges such as inefficient drug delivery due to homogenous distribution of active components, leading to significant waste and limited control over dosage and quantity, especially in delivering combinations of antigens and adjuvants for vaccine applications.
Innovation Solution
The development of dissolvable microneedle arrays with active components concentrated in the needle tips, using novel fabrication techniques like sequential micro-molding and spin-drying, and micromilling, allows for efficient and precise delivery of bioactive molecules by localizing the active components in the tips and using less expensive, non-active matrix materials for the rest of the array.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of substance
If active components are homogenously embedded in microneedles and support structures using conventional microcasting processes, then the fabrication process is simple, but significant waste of active components occurs and dosage control is limited
Solution Approach 1:
The patent applies local quality by concentrating active components specifically in the needle tips rather than homogeneously distributing them throughout the entire microneedle array including support structures. This is achieved through a multi-step fabrication process where active components are first embedded in needle tips, then non-active matrix material is added to form the support structures, thereby eliminating waste of active components in non-functional areas.
Solution Approach 2:
The fabrication process is segmented into distinct steps: first forming needle tips with active components, then separately adding non-active matrix material for support structures. This segmentation allows precise control over where active components are located, preventing their unnecessary inclusion in support structures and reducing waste.
2Manufacturing precision
If active components are concentrated in needle tips using novel fabrication techniques, then drug delivery precision and efficiency improve, but fabrication process complexity increases
Solution Approach 1:
The patent employs preliminary action by first forming the needle tips and embedding active components in them before adding the non-active matrix material. This sequential approach ensures precise dosage control from the outset, as active components are positioned exactly where needed in the needle tips before the support structure is completed.
Solution Approach 2:
The patent uses non-active matrix material as an intermediary substance that is added after the active components are in place. This intermediary material forms the support structures without interfering with the precisely positioned active components, allowing complex functionality to be achieved while maintaining manufacturing feasibility.
3Ease of manufacture
If non-active matrix materials are used for support structures, then economic feasibility improves, but structural integrity must be maintained
Solution Approach 1:
The patent segments the microneedle array into functional components: needle tips containing active components and support structures made of non-active matrix material. This segmentation allows the use of cost-effective non-active materials for the support structures while maintaining structural integrity, as these materials are specifically engineered to provide mechanical strength without containing expensive active components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces waste, increases drug concentration in the skin-penetrating needle tips, enhances economic feasibility, and improves the delivery capacity of bioactive components, enabling simultaneous delivery of multiple chemically distinct agents for enhanced immune responses and therapeutic applications.
Implementation Method 1
The microneedle array delivery platforms can be used to deliver a broad range of bioactive components to a patient
Implementation Method 2
dissolvable microneedle arrays with active components concentrated in the needle tips
Data Source
Figure 1~2
Figure 3A~4B
Figure 5A~6B
AI summary
A method of forming a microneedle array can include forming a microneedle array that has one or more bioactive component. The microneedle array can include a base portion and plurality of microneedles extending from the base portion, and the one or more bioactive components are present in a higher concentration in the plurality of microneedles than in the base portion.